KR20080108221A - 출혈성 쇼크 및 그 후유증의 치료용 약제 조성물 - Google Patents

출혈성 쇼크 및 그 후유증의 치료용 약제 조성물 Download PDF

Info

Publication number
KR20080108221A
KR20080108221A KR1020087017988A KR20087017988A KR20080108221A KR 20080108221 A KR20080108221 A KR 20080108221A KR 1020087017988 A KR1020087017988 A KR 1020087017988A KR 20087017988 A KR20087017988 A KR 20087017988A KR 20080108221 A KR20080108221 A KR 20080108221A
Authority
KR
South Korea
Prior art keywords
pro
arg
gly
peptide
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087017988A
Other languages
English (en)
Korean (ko)
Inventor
페터 페첼바우어
라이너 헤닝
Original Assignee
피브렉스 메디칼 리서치 앤드 디벨롭먼트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피브렉스 메디칼 리서치 앤드 디벨롭먼트 게엠베하 filed Critical 피브렉스 메디칼 리서치 앤드 디벨롭먼트 게엠베하
Publication of KR20080108221A publication Critical patent/KR20080108221A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020087017988A 2005-12-23 2006-11-10 출혈성 쇼크 및 그 후유증의 치료용 약제 조성물 Ceased KR20080108221A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0206705A AT502987A1 (de) 2005-12-23 2005-12-23 Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
ATA2067/2005 2005-12-23

Publications (1)

Publication Number Publication Date
KR20080108221A true KR20080108221A (ko) 2008-12-12

Family

ID=37846035

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087017988A Ceased KR20080108221A (ko) 2005-12-23 2006-11-10 출혈성 쇼크 및 그 후유증의 치료용 약제 조성물

Country Status (14)

Country Link
US (1) US7897574B2 (https=)
EP (2) EP1962887B1 (https=)
JP (1) JP2009520696A (https=)
KR (1) KR20080108221A (https=)
CN (1) CN101365477A (https=)
AT (2) AT502987A1 (https=)
AU (1) AU2006326890A1 (https=)
CA (1) CA2634026A1 (https=)
DE (1) DE502006004619D1 (https=)
ES (1) ES2331970T3 (https=)
IL (1) IL192349A0 (https=)
NO (1) NO20083191L (https=)
RU (1) RU2008130413A (https=)
WO (1) WO2007070899A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641908A1 (en) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
JP2010540892A (ja) * 2007-09-24 2010-12-24 ファイブレックス メディカル リサーチ アンド デベロップメント ゲーエムベーハー 抗炎症活性を有する化合物をスクリーニングする方法
US20130324469A1 (en) * 2010-12-09 2013-12-05 The Brigham And Women's Hospital, Inc. Fibrinogen and kidney damage
TW201718028A (zh) * 2015-10-13 2017-06-01 賽米克Ｉｐ有限責任公司 Ve-鈣黏蛋白結合性生物結合物
JP7506364B2 (ja) * 2019-10-24 2024-06-26 国立大学法人東海国立大学機構 慢性肺疾患／急性呼吸窮迫症候群の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997844A (en) 1991-02-08 1999-12-07 Diatide, Inc. Technetium-99m labeled peptides for imaging
BR0116122A (pt) 2000-12-12 2003-10-14 Fibrex Medical Res & Dev Gmbh Peptìdeos e/ou proteìnas bem como seu uso para preparar uma composição farmacêutica, terapêutica e/ou preventiva
US20080311103A1 (en) * 2004-03-08 2008-12-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Anti-Inflammatory Peptides and Methods of Use Thereof
AT414097B (de) 2004-06-25 2006-09-15 Petzelbauer Peter Dr Pharmazeutische zubereitung zur behandlung von schock
DK1691827T3 (da) * 2004-06-25 2009-12-14 Fibrex Medical Res & Dev Gmbh Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock

Also Published As

Publication number Publication date
ATE440282T1 (de) 2009-09-15
NO20083191L (no) 2008-09-16
CN101365477A (zh) 2009-02-11
AU2006326890A1 (en) 2007-06-28
EP1962887A2 (de) 2008-09-03
EP2110136A2 (de) 2009-10-21
US20090005310A1 (en) 2009-01-01
JP2009520696A (ja) 2009-05-28
EP2110136A3 (de) 2010-01-27
DE502006004619D1 (de) 2009-10-01
RU2008130413A (ru) 2010-01-27
EP1962887B1 (de) 2009-08-19
ES2331970T3 (es) 2010-01-21
WO2007070899A3 (de) 2007-10-04
AT502987A1 (de) 2007-07-15
CA2634026A1 (en) 2007-06-28
US7897574B2 (en) 2011-03-01
WO2007070899A2 (de) 2007-06-28
IL192349A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
Sandset et al. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant.
US20050272634A1 (en) Use of erythropoietin
EP2996713B1 (en) Compositions and methods for treating post-operative complications of cardiopulmonary surgery
EP2987498B1 (en) Treatment of bleeding with low half-life fibrinogen
KR20230024352A (ko) C형 나트륨이뇨 펩타이드 및 이의 급성 폐 손상의 치료에서의 방법
KR20080108221A (ko) 출혈성 쇼크 및 그 후유증의 치료용 약제 조성물
EP1691827B1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
CN103536610B (zh) 三七皂苷Fc的医药用途
TWI441645B (zh) 作為新穎之局部用止血劑的活化型因子Ｘ（ＦＸａ）刺激劑
KR20190111912A (ko) 출혈의 치료 또는 예방에 사용하기 위한 혈액 응고 인자 대체품
JP2020530012A (ja) ディスインテグリン変異体及びその使用法
MX2008008324A (en) Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms
CN119684441B (zh) 一种衍生多肽pm6及其在抗血栓中的应用
JP2002060345A (ja) 血液凝固能異常に係わる疾患の予防・治療剤
WO2008038777A1 (en) Therapeutic agent for disseminated intravascular coagulation syndrome
WO2026006884A1 (en) Modulators of fxii-upar
AT501263B1 (de) Pharmazeutische zubereitung zur behandlung von schock
JP2015063498A (ja) 新規なポリペプチド及びその用途
WO2004103397A1 (en) Compositions comprising factor viii and factor ixa for treating haemophilia
JPWO2020084853A1 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
De Curtis et al. A procyanidin extract prolongs bleeding time but does not prevent thrombosis in rats
Chiba Serum transfusion as a hemostatic procedure
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
JP2007262027A (ja) Ａｔ−ｉｉｉによる内因性ｉｇｆ−１の産生誘導剤
NZ553426A (en) Use of erythropoietin for treating diabetes mellitus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080722

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110523

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130329

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130829

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130329

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I